HEALTH

CHPA dextromethorphan awareness initiative a finalist in healthcare campaign awards

BY Michael Johnsen

WASHINGTON A grass roots online media campaign to raise awareness around the dangers of dextromethorphan abuse was a finalist for PRWeek’s Healthcare Campaign of the Year, the Consumer Healthcare Products Association, which sponsored the Five Moms online initiative with assistance of Edelman Public relations, announced Friday.

The awards ceremony took place March 6 in New York.

More than 900 entries were received this year. The Healthcare Campaign of the Year category also included CHPA member company GlaxoSmithKline Consumer Healthcare, for its OTC launch of alli. It was Weber Shandwick and the National Marrow Donor Program: 2007 Thanks Mom National Marrow Donor Drive, however, that won the 2008 award in this category.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Abkit rolls out new flavors of Zucol Coldcare

BY Michael Johnsen

DESTIN, Fla. Abkit, which launched its two Zucol Coldcare exclusively in Rite Aid earlier this year, showcased its menthol- and orange creme-flavored homeopathic SKUs to buyers at the ECRM Cough & Cold and Allergy here this past week. The same formula marketed by parent company Schwabe is the No. 1 OTC brand in Germany, under the Umckaloabo brand name, where it generates $230.7 million in annual sales, Abkit executives reported.

The homeopathic ingredients in Zucol are supported by some 19 clinical trials which included results from almost 3,000 patients.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Zyrtec-D added to Perrigo’s private label

BY Michael Johnsen

ALLEGAN, Mich. Perrigo on Thursday added Zyrtec-D to its private label offerings, following final Food and Drug Administration approval of Teva Pharmaceutical’s abbreviated new drug application for an over-the-counter version of cetirizine hydrochloride, pseudoephedrine hydrochloride extended-release tablets, 5 mg/120 mg.

According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the 12 months ending December 2007 were approximately $190 million.

“This approval and marketing agreement reflect our strategy to be first to market with the important products that make quality healthcare more affordable for our customers and drive value for our shareholders,” stated Perrigo’s chairman and chief executive officer Joseph Papa.

Perrigo expects to begin shipping the product in the next 90 days.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES